otherwise requires all references in this document to we us or our refers to

Otherwise requires all references in this document to

This preview shows page 26 - 30 out of 124 pages.

otherwise requires, all references in this document to “we”, “us” or “our” refers to Sun Pharmaceutical Industries Limited and consolidated subsidiaries. %P%]P_*9$>Me [1] IMS Health, Cost containment within healthcare markets, 2011 [2] IMS Health: Market Prognosis, April 2011 f6g IMS Health: US Pharmaceutical Market [4] IMS Health, Global Use of Medicines Report, May 2011 [5] >KDUjDFHXWLFDO#([HFXWLYH/#$XJXVW#5344 [6] Pharma Times [7] Pharma Voice, 2012 [8] M?%&0#PQGLD#>KDUjDFHXWLFDO [9] (GHOZHLVV#²#PQGLD#>KDUjDFHXWLFDOV [10] IMS Health: National Sales Perspective, December, 2011 [11] IMS Health: The US Pharmaceutical Market, March 2012 [12] USFDA, IMS Morgan Stanley Research, 2011 f46g P^?0#'UXJ#?KRUWDJH#9HSRUW/#$?>(#UHSRUW#RQ#GUXJ#VKRUWDJHV [14] Motilal Oswal Securities Limited Research Report, November 2011 [15] FDA [16] PharmaTimes, emerging markets and new emerging market segments [17] (GHOZHLVVB#PQGLD#>KDUjDFHXWLFDOV [18] (GHOZHLVV#0>KDUjD#^RQWKO\ [19]&UHGLW#?XLVVHB#>KDUjD#9HÁHFWLRQV#5345 (GHOZHLVVB#PQGLD#>KDUjD [21] Motilal Oswal Securities Limited- Report on Domestic Formulations, August 2011 [22] PQGLD#%UDQG#(TXLW\#ERXQGDWLRQ# f56g IDFC: India Pharma [24] SMSRC November 11- February12
Image of page 26
Sun Pharmaceutical Industries Ltd. ?a$aba_9e#9(>_9a? Directors’ Report 26 Corporate Governance 65 [email protected]'$][email protected](#[email protected][email protected]&P$]#?a$a(^(@a? Auditors’ Report 46 %DODQFH#?KHHW 50 ?WDWHjHQW#RI#>URÀW#DQG#]RVV#$FFRXQW 51 Cash Flow Statement 52 Notes 54 [email protected]?_]P'$a('#[email protected][email protected]&P$]#?a$a(^(@a? Auditors’ Report 86 %DODQFH#?KHHW 88 ?WDWHjHQW#RI#>URÀW#DQG#]RVV#$FFRXQW 89 Cash Flow Statement 90 Notes 92
Image of page 27
26 On Course Your Directors take pleasure in presenting the Twentieth Annual Report and Audited Accounts for the year ended March 31, 2012. Financial Results ( ` in million except dividend per share and book value) Particulars Year ended March 31, 2012 Year ended March 31, 2011 Total Income 43584 33017 Profit after tax 16975 13838 Dividend on Equity Shares 4401 3625 Corporate Dividend tax 714 588 Transfer to various Reserves 2000 5000 Amount of dividend per equity share of ` 1/- each 4.25 3.5 Book value per equity share of ` 1/- each 76 65 Dividend An interim equity dividend of ` 4.25 per equity share of face value ` 1/- each (previous year ` 3.50 per equity share) for the year ended March 31, 2012 as recommended by the Board of Directors of the Company at their Meeting held on August 10, 2012 was paid on August 22, 2012 to the Equity Shareholders of the Company whose names stood on the Register of Members on August 16, 2012. Yours Directors recommend that the interim dividend paid as aforesaid be treated as final for the year ended March 31, 2012. Management Discussion and Analysis The Management Discussion and Analysis on the operations of the Company is provided in a separate section and forms part of this report. DIRECTORS’ Report NMR, Analytical lab, SPARC
Image of page 28
Annual Report 2011-12 27 Sun Pharmaceutical Industries Ltd. HIGHLIGHTS STATUTORY REPORTS FINANCIAL STATEMENTS DIRECTORS’ Report CRISIL continued to reaffirm its highest rating of “AAA/ Stable” and “A1+”, for your Company’s Banking Facilities throughout the year Scheme of Arrangement in the form of spin off and transfer of Domestic Formulation Division of our Company to Sun Pharma Laboratories Ltd., a wholly owned subsidiary of our Company with
Image of page 29
Image of page 30

You've reached the end of your free preview.

Want to read all 124 pages?

  • Spring '11
  • Thampy,Ashok
  • Pharmacology, Pharmaceutical drug, Food and Drug Administration, Sun Pharmaceutical Industries Limited, Sun Pharmaceutical Industries

  • Left Quote Icon

    Student Picture

  • Left Quote Icon

    Student Picture

  • Left Quote Icon

    Student Picture